Interpace shareholders approve reverse split up to 1-for-10, equity plans, and director slate

INTERPACE BIOSCIENCES, INC.

Reverse stock split authorized (1:2 to 1:10 ratio, board discretion within 1 yr): 26,180,980 for, 397,262 against.
Amended & restated certificate of incorporation approved: 24,981,181 for, 246,552 against, 3,625 abstain.
All five director nominees elected, incl. CEO Thomas W. Burnell (25,095,783 for) and Joseph D. Keegan (24,422,783 for).
2026 Equity Incentive Plan approved: 24,887,762 for; 2026 Employee Stock Purchase Plan: 24,580,773 for.
Say-on-pay passed (24,952,970 for); EisnerAmper LLP ratified as auditor (26,442,760 for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.